中國聖牧(01432.HK)附屬聖牧高科就訴訟向內蒙法院上訴
中國聖牧(01432.HK)表示,呼和浩特市中級人民法院於今年8月16日發出民事判決書,判令間接全資附屬公司聖牧高科和兩名前董事向原告人支付1.18億元人民幣(下同)款項及1,644.25萬元利息,以及律師費4萬元與訴訟費用72.1萬元。
就有關訴訟,中國法院凍結聖牧高科的若幹銀行賬戶,總結餘約8,570.5萬元,及聖牧高科所持有的附屬公司巴彥淖爾市聖牧六和牧業有限公司65%的股權。
公司指,聖牧高科不同意判決,並已於9月10日向內蒙古自治區高級人民法院提出上訴,自收到判決以來一直與公司顧問合作,以確定該宗訴訟對集團的整體業務運作及財務狀況的影響以及其可能或應該採取的任何其他步驟。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.